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Bovine pancreatic trypsin inhibitor
NMR spectroscopy
Closed/active conformationa b s t r a c t
One approach to treating the dengue virus infection is to inhibit its NS2B-NS3 protease that plays a
vital role in virus maturation. However, the lack of structural information on the active conforma-
tion of the protease hindered related drug design. With a co-expression system, we obtained the
active two-component protease in its unlinked form. BPTI shows strong competitive inhibitory
activity (Ki = 6.5 nM) against this unlinked protease, which adopts a closed conformation. Based
on the biochemical and NMR perturbation information, an inhibition model of BPTI to NS2B-NS3
protease is proposed.
Structured summary of protein interactions:
NS3p and NS2B bind by molecular sieving (View interaction)
NS3p, NS2B and BPTI physically interact by isothermal titration calorimetry (View interaction)
NS3p, NS2B and BPTI physically interact by molecular sieving (View interaction)
NS3p, NS2B and BPTI physically interact by nuclear magnetic resonance (View interaction)
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Dengue virus (DENV) belongs to the Flaviviridae family. Infec-
tion of any of the four serotypes of DENV will lead to dengue fever,
or the more severe dengue hemorrhagic fever (DHF) and dengue
shock syndrome (DSS). It is estimated that there are 390 million
infections per year, of which 96 million become manifest [1].
Unfortunately, neither approved vaccine nor effective antiviral
drug is available despite the great deal of study carried out in the
past few decades.
The dengue virus genome encodes a poly-protein precursor,
which can be further processed into several components by host
peptidases and viral proteases. The N-terminal segment of the
non-structural protein 3 (NS3) is a trypsin-like protease (NS3p)
and its proteolytic activity requires the cofactor NS2B. In the pres-
ence of NS2B, the NS3p activity will be increased by 3300–6600
folds [2]. The two-component protease NS2B-NS3p is indispensible
during the viral life cycle for its capability of processing the protein
precursor. Therefore, the dengue virus NS2B-NS3p is widely con-
sidered a potential target for anti-virus drugs.The NS2B.Gly.NS3p construct, also named linked NS2B-NS3p,
was successfully produced and demonstrated to be catalytically
active in 2001 [3]. Its crystal structure was determined subse-
quently [4]. But in the structure, the C-terminal part of NS2B
(NS2B-C) does not interact with the active site of NS3p and the
overall structure adopts a so-called open form (Fig. 1A). NS2B-
NS3p from West Nile virus (WNV), which also belongs to the
Flaviviridae family, shares about 50% sequence identity with DENV
NS2B-NS3p. However, in the inhibitor bound structure of WNV
NS2B-NS3p, NS2B-C adopts a closed form (Fig. 1B) [4–6]. In this
closed conformation, the NS2B-C wraps around NS3p and directly
inserts its b-hairpin into the active site of NS3p, resulting in an
intact active pocket [4–6]. Thus, the open form is thought of as
the inactive conformation, and the closed form the active. Many
competitive inhibitors targeting the DENV NS2B-NS3p active site
[7–9] and some allosteric inhibitors targeting NS2B [10,11] were
designed, but they were all based on either the open form of DENV
NS2B-NS3p or models from the closed form of WNV NS2B-NS3p.
The lack of structural information on the closed form of DENV
NS2B-NS3p clearly hinders the rational design of inhibitors for
DENV. Recently, the BPTI-bound structure of DENV3 NS2B-NS3p
was determined [12]. The NS2B portion of DENV3 displayed a sim-
ilar conformation to that of WNV in the inhibitor bound form.
However, life-threatening diseases such as DHF and DSS are
Fig. 1. Two different conformations of NS2B-NS3p. (A) The open conformation of NS2B-NS3p in the crystal structure of DENV2 NS2B-NS3p. (PDB ID: 2FOM). (B) The closed
conformation in the crystal structure of WNV NS2B-NS3p bound with BPTI (PDB ID: 2IJO). NS3p is shown in cyan. N-terminal part of NS2B is shown in marine, while C-
terminal part of NS2B (NS2B-C) in orange. NS2B-C departs from NS3p in open conformation, while it forms tight interactions with NS3p in closed conformation.
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ent serotype due to antibody dependent enhancement [13]. The
closed form structure of NS2B-NS3p from DENV2, the most studied
serotype among the four, has yet to be determined. An earlier NMR
study on DENV2 NS2B-NS3p showed that small molecule inhibi-
tors could induce the shift from the open form to the closed form
[14]. A follow-up NMR study on a cleavable NS2B-NS3p construct
demonstrated that DENV2 NS2B-NS3p could assume the closed
form without inhibitors [15]. Recently, a new construct for DENV2
called ‘‘unlinked NS2B-NS3p’’, in which NS2B and NS3p were sub-
cloned into different vectors and co-expressed in Escherichia coli,
was constructed [16]. This unlinked protease was enzymatically
active and existed predominantly in the closed form similar to
the ligand bound NS2B-NS3p complex.
In this work, we generated a new construct that is similar to the
unlinked protease. This NS2B-NS3p protease also existed in closed
form in solution. For the ﬁrst time, we demonstrated that BPTI
(bovine pancreatic trypsin inhibitor, also known as aprotinin)
inhibited the unlinked protease competitively. Combining the bio-
chemical and NMR chemical shift perturbation data, we proposed
an inhibition model of BPTI binding to DENV NS2B-NS3p.
2. Materials and methods
2.1. Cloning, expression and puriﬁcation
The genes encoding DENV2 NS2B (49-95) and NS3p (1-185)
were ampliﬁed by PCR using the fusion DENV2 NS2B-NS3p plas-
mid [17] as templates. Then the PCR product of NS2B was sub-
cloned into the NdeI and XhoI sites of pETDuet-1 to generate the
expression plasmid of pETDuet-NS2B. NS3p was subcloned into
the NdeI and XhoI sites of pACYCDuet to generate the expression
plasmid of pACYCDuet-NS3p with an N-terminal His-6 tag. pETD-
uet-NS2B and pACYCDuet-NS3p were co-transformed into E. Coli
BL21(DE3) competent cells. Cells harboring pETDuet-NS2B and
pACYCDuet-NS3p were cultured in 5 mL of LB broth containing
both 34 lg/mL of chloramphenicol and 100 lg/mL of ampicillin
at 37 C overnight. The cells were harvested and transferred into
M9 medium until the OD600 reached 0.6. Then the cultures were
induced by 0.5 mM IPTG at 37 C for 4 h. Finally, cells were col-
lected by centrifugation at 8000g for 8 min at 4 C. For protein
puriﬁcation, the harvest cells were resuspended in buffer A con-
taining 20 mM NaH2PO4 (pH 7.8) and 500 mM NaCl and disrupted
by two passes through a high-pressure cell homogenizer at
1.3 MPa. Cell debris was removed by centrifugation at 18000g
for 2  20 min, and the supernatant was mixed with Ni2+-NTAresin pre-equilibrated with buffer A and incubated for 2 h. Resin
with protein was washed with buffer A and 100 mM imidazole to
remove contaminant proteins. The unlinked NS2B-NS3p was
eluted by buffer A and 500 mM imidazole. Fractions containing
the target protein were ﬁrst buffer-exchanged to 20 mM Tris (pH
8.0) using a HiPrep 26/10 desalting column and then loaded onto
a Source Q anion-exchange column pre-equilibrated with 20 mM
Tris (pH 8.0). Fractions eluted by a linear gradient of 80–250 mM
NaCl on Source Q were collected and further puriﬁed by gel ﬁltra-
tion using Superdex 75 column. The gel ﬁltration buffer was
20 mM Tris–HCl (pH 7.5) and 100 mM NaCl. All puriﬁcations were
performed at 4 C. For 15N-, 15N/13C- or 15N/13C/2H-labeled
proteins, the cells were grown in H2O or D2O containing M9 min-
imal medium supplemented with 13NH4Cl or/and 15C-glucose,
respectively.
2.2. Isothermal titration calorimetry (ITC) experiment
ITC measurements were carried out on an iTC200 microcalorim-
eter (MicroCal Inc.) at 20 C. Protein samples were dialysed against
an ITC buffer of 20 mM Tris (pH 7.5) and 50 mM NaCl overnight at
4 C. BPTI (purchased from sigma) was then dissolved using the ITC
buffer after dialysis. All solutions were degassed before titrations
were performed. The sample cell was ﬁlled with 200 lL protein
in 20 lM and the syringe was ﬁlled with 40 lL BPTI in 300 lM.
During each experiment, 0.4 lL BPTI was ﬁrst injected into the
sample cell, followed by 19 injections of 2 lL BPTI at intervals of
60 s. In order to deduct the heat of the dilution, the ITC buffer
was injected into the protein solution under the same conditions.
The raw titration data was analyzed using Origin 7.0 provided by
MicroCal. The calculated KD value was the average of triplicate
measurements.
2.3. Inhibition assay
The inhibition assay was performed on a Mithras2 multimode
reader (BertholdTech) at 37 C. All samples were prepared in a buf-
fer consisting of 20 mM Tris–HCl (pH 7.5), 0.01% Triton X-100. The
unlinked NS2B-NS3p was incubated with 0–20 nM BPTI at 37 C for
3 min for pre-equilibration. Then the substrate Benzoyl-Nle-Lys-
Arg-Arg-AMC (purchased from Bachem) [18] was added into the
reaction mixture (ﬁnal volume 100 lL) to a ﬁnal concentration of
100 or 200 lM. The remaining enzyme activity was monitored by
the increase of ﬂuorescence (exciting at 356 nm and monitoring
the emission at 438 nm) with a 20 min measurement period. Using
the initial velocities of the reactions, the inhibition constant (Ki) of
Fig. 2. Puriﬁcation of the unlinked NS2B-NS3p. (A) Diagram of the unlinked NS2B-
NS3p used in this study. The sequence number of NS2B was marked with ⁄ to
differentiate from NS3p. (B) SDS–PAGE analysis for the puriﬁcation step of the
unlinked NS2B-NS3p. M is the molecular weight marker. Lane 1 is the supernatant
after disruption followed by centrifugation. Lane 2 is the fractions puriﬁed by Ni2+-
NTA resin. Lane 3 is the puriﬁed fraction from Source Q. Lane 4 is the puriﬁed
unlinked NS2B-NS3p by gel ﬁltration chromatography.
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Dixon plot [19] (1/v values against concentration of BPTI) from
two different concentrations of the substrate (100 and 200 lM).
Data from triplicate measurements were used in the calculation.Fig. 3. Interactions between the unlinked NS2B-NS3p with BPTI. (A) Gel ﬁltration and
molecular weight marker. Lane 1 is the puriﬁed unlinked NS2B-NS3p by gel ﬁltration chro
NS2B-NS3p from gel ﬁltration chromatography. (B) Isothermal titration calorimetry analy
NS3p. The concentrations of Benzoyl-Nle-Lys-Arg-Arg-AMC are 100 lM (d) and 200 lM (2.4. NMR spectroscopy
All NMR spectra were acquired at 30 C on Bruker Avance 600 or
850 MHz NMR spectrometers, equipped with a triple-resonance
cryoprobe with pulsed ﬁeld gradients. The NMR samples were con-
centrated to 0.5 mM for backbone assignment and 0.2 mM for
BPTI titration in an NMR buffer containing 20 mM Na2HPO4/NaH2
PO4 (pH 7.0), 100 mM NaCl. For NS2B-NS3p/BPTI samples, BPTI
was dissolved in the NMR buffer and added into the protease at
a molar ratio of 2:1. The backbone 15N, 1HN, 13Ca, 13Cb and 13CO
chemical shifts were assigned as previously described [17]. Chem-
ical shift perturbations for backbone 1HN and 15N resonances were
calculated by the equation Dd ¼ ½ðDdHNÞ2 þ ð0:17DdNÞ2
0:5
. All NMR
spectra were processed by the use of nmrPipe [20] and analyzed by
the use of SPARKY (T.D. Goddard and D.G. Kneller, SPARKY 3,
University of California, San Francisco).
2.5. Computational modeling
The closed conformation of the unlinked DENV2 NS2B-NS3p
was modeled by MODELER inside Discovery Studio 3.1 package
(Accelrys Inc.) using the crystal structure of WNV NS2B-NS3p com-
plexed with BPTI (PDB ID: 2IJO) [5] as a template. The NS2B-NS3p
from DENV2 and WNV share 46.8% sequence identity. The validity
of the closed model of the unlinked DENV2 NS2B-NS3p was
assessed by VERIFY-3D in Discovery Studio 3.1. Then the model
was superimposed to the crystal structure of WNV NS2B-NS3p
complexed with BPTI (PDB ID: 2IJO) to obtain the putative inhibit-
ing model of BPTI to the unlinked DENV2 NS2B-NS3p.SDS–PAGE analysis for the mixture of BPTI and the unlinked NS2B-NS3p. M is the
matography. Lane 2 is the puriﬁed fractions for the mixture of BPTI and the unlinked
sis of BPTI to NS2B-NS3p. (C) Dixon plot of the inhibition assay of BPTI against NS2B-
s). The inhibitory constant value (Ki) is determined using linear regression analysis.
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3.1. Expression and puriﬁcation of the unlinked NS2B-NS3p
Up to date, the structure of the active form of DENV2 NS2B-
NS3p still remains unknown. We observed severe spectral overlap
in the linked protease when we tried to study its conformation byFig. 4. NMR investigations of the unlinked NS2B-NS3p/BPTI complex. (A) The amide reson
(red) or presence (black) of BPTI. The amide resonances in BPTI-free state are indicated. (
the equation Dd ¼ ½ðDdHNÞ2 þ ð0:17DdNÞ2
0:5
. The black line indicates 0.153 ppm (mean +
mapping of chemical shift perturbations of the unlinked NS2B-NS3p/BPTI complex. The re
showed as sticks. The other residues of NS2B and NS3p are colored the same as in Fig. 1NMR spectroscopy. A recent study reported a version of unlinked
protease that was suitable for NMR studies with dispersed spec-
trum [16]. However, we were not able to obtain the unlinked
protease using the exact same strategy. It is possible that the codon
of NS3p was optimized during their synthesis. Nevertheless, we
obtained a similar construct of unlinked DENV2 NS2B-NS3p
(Fig. 2A) using co-expression system, and puriﬁed it throughances of the overlaid 2D 1H, 15N TROSY-HSQC spectra for NS2B-NS3p in the absence
B) Chemical shift perturbations for backbone 1HN and 15N resonances calculated by
S.D.). The vertical dash line separates the residues of NS2B and NS3p. (C) Structural
sidues with chemical shift perturbation >0.153 ppm are in red. The catalytic triad is
.
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Superdex75 gel ﬁltration column (Fig. 2B).
3.2. BPTI, as a competitive inhibitor, binds to the unlinked NS2B-NS3p
BPTI is a well-known trypsin inhibitor and its inhibition activity
to linked DENV2 NS2B-NS3p has been documented [3]. The BPTI
bound NS2B-NS3p complex is an ideal model for studying the
active conformation of the linked NS2B-NS3p [5]. BPTI binding to
the unlinked NS2B-NS3p was conﬁrmed by the elution curve from
gel ﬁltration puriﬁcation for the mixture of BPTI and the unlinked
NS2B-NS3p. There was only one symmetrical peak that contained
both the unlinked NS2B-NS3p and BPTI revealed by SDS–PAGE
analysis (Fig. 3A). To further investigate the direct interaction
between BPTI and the unlinked NS2B-NS3p, we performed isother-
mal titration calorimetry (ITC) measurements. The binding curve
reveals that BPTI binds to the unlinked NS2B-NS3p strongly with
a KD value of 18.3 nM and 1:1 stoichiometry (Fig. 3B). The Dixon
plot analysis from the inhibition assay data shows that BPTI
behaves as a competitive inhibitor against the unlinked NS2B-
NS3p with an inhibitory constant value (Ki) of 6.5 nM (Fig. 3C).
Taken together, the BPTI bound unlinked NS2B-NS3p complex is
a suitable model for studying the active conformation of NS2B-
NS3p.
3.3. Mapping the BPTI interaction site of the unlinked NS2B-NS3p
We previously reported the backbone assignments of the linked
protease in complex with BPTI [17]. The good match of the
2D-TROSY-HSQC spectra of the unlinked protease and the BPTI
bound linked protease indicates the same conformation and
assignments, except for some N- and C-terminal residues of NS3p.
We detected the BPTI binding site of the unlinked NS2B-NS3p
by measuring chemical shift perturbations of amide resonances
of the unlinked NS2B-NS3p with BPTI binding (Fig. 4A). The pertur-
bations were calculated and mapped onto the structure model of
the unlinked NS2B-NS3p (Fig. 4B, C). The residues, with signiﬁcant
chemical shift perturbations of amide resonances upon BPTI bind-
ing (Dd > mean + S.D.), were located mainly at the active pocket.
Residues around the catalytic triad (His51, Asp75, and Ser135)
showed signiﬁcant chemical shift perturbations (Fig. 4C), such as
Thr48-His51, Thr53, Leu76, Ile77, and Gly136. Meanwhile,
Gly151 and Ala166, in the proximity of the catalytic triad in struc-
ture, also exhibited notable chemical shift perturbations. Ile78⁄
and Met84⁄ from NS2B-C also showed signiﬁcant chemical shift
perturbations, indicating that this part of NS2B-C can participate
in the forming of the active pocket and is involved in the bindingFig. 5. Putative inhibitory model of BPTI to the unlinked NS2B-NS3p. (A) The interaction
BPTI is showed in green cartoon, and residues binding to NS2B-NS3p shown as sticks. Th
The interface probed by NMR perturbation. The surface of those residues with chemicalto BPTI. Some other residues far away from the catalytic triad, such
as Gln27 and Gly32, also exhibited signiﬁcant chemical shift per-
turbations. This may result from conformational change induced
by BPTI binding to NS2B-NS3p.
3.4. Putative inhibition model of BPTI to the unlinked NS2B-NS3p
The putative inhibitory model of BPTI to the unlinked NS2B-
NS3p was obtained through superimposing BPTI bound WNV
NS2B-NS3p to the unlinked NS2B-NS3p, which was modeled using
the closed conformation of the WNV NS2B-NS3p as a template [5].
The model shows that BPTI almost occupies the entire active
pocket of the unlinked NS2B-NS3p (Fig. 5A). The binding surface
of the NS2B-NS3p includes most of the residues around the cata-
lytic triad. The result from computational modeling corroborates
well with the NMR chemical shift perturbation data (Fig. 5B).
4. Discussion
The two-component protease dengue virus NS2B-NS3p plays a
vital role in viral survival and is thus considered to be a target
for therapeutic intervention for dengue virus infection. Many
efforts have been made to design drugs targeting DENV NS2B-
NS3p [7–11]. However, the most commonly used construct exhib-
ited predominantly (more than 90%) in open form in solution
[21,22]. The active NS2B-NS3p, including the WNV NS2B-NS3p,
assumes the closed conformation [5,12,14]. It is not surprising that
so far there has been little success as most designs were based on
the inactive conformation. Therefore, acquisition of the active con-
formation of NS2B-NS3p is imperative for successful drug design.
In this study, we obtained an unlinked NS2B-NS3p that is
proteolytic active using the similar co-expression system [16].
Upon BPTI binding, we observed no signiﬁcant chemical shift per-
turbations for the majority of the resonances, suggesting that
NS2B-NS3p preserves the closed conformation. Ile78⁄, Met84⁄
and several neighboring residues from NS2B-C, which is assumed
to insert into the active site in the NS2B-NS3p apo conformation,
show stronger chemical shift perturbations, indicating obvious
chemical environment changes upon BPTI binding. This is consis-
tent with the fact that NS2B-C is a co-factor for protease activity
[4].
Furthermore, BPTI inhibits the unlinked NS2B-NS3p competi-
tively (Fig. 3C). This suggests that BPTI inhibits the proteolytic
activity by blocking the active site pocket. After the binding of BPTI,
some signiﬁcant chemical shift perturbations were observed and
mapped on a model of the unlinked NS2B-NS3p. Overall, the resi-
dues with signiﬁcant chemical shift perturbations are locatedinterface between BPTI and the unlinked NS2B-NS3p by computational modeling.
e region of NS2B-NS3p that is within 3.5 Å away from BPTI is colored in salmon. (B)
shift perturbation >0.153 ppm is in red.
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(Fig. 4). This is similar to that of the BPTI bound linked NS2B-
NS3p and implies the important role NS2B-C plays in proteolytic
activity. Surprisingly, one of the catalytic triad residues His51
and some residues around it show strong chemical shift perturba-
tion upon binding with BPTI (Fig. 4). In the crystal structure of the
linked NS2B-NS3p, this region does not directly interact with BPTI
[5,12]. This implies that this region in our model may be directly
involved in the inhibitor binding.
The unlinked and linked NS2B-NS3p share some similar proper-
ties, including proteolytic activity and secondary structure. But the
subtle change in construct may lead to different active conforma-
tion. NS2B and NS3p, covalently linked by the natural cleavage site,
were expressed in two separate segments through autoproteolytic
cleavage recently [15]. In their study, the closed conformation also
populated to a large extent. Taken together, the unlinked version of
NS2B-NS3pmimics the natural state better than the linked version.
Through computational modeling, a binding model of BPTI to the
unlinked NS2B-NS3p is proposed. This model ﬁts the biochemical
and NMR chemical shift perturbation data well but needs to be fur-
ther conﬁrmed experimentally by X-ray crystallography or NMR
analysis.
In summary, our work presents a new choice for unlinked den-
gue NS2B-NS3p that is enzymatically active and mainly exists in
active conformation in solution. The residues that could interact
with inhibitor were mapped out. This will provide a new frame-
work for better understanding DENV NS2B-NS3p and will facilitate
future drug designs against DENV.
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